Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human brain natriuretic peptide in diuretic-resistant fluid overload after cardiac surgery
ChiCTR2500108379Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of nesiritide in hypervolemia, Diuretic resistance and acute kidney failure (AKF) (2 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Incidence of renal replacement therapy (RRT). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
hypervolemiaDiuretic resistanceacute kidney failure (AKF)
Beyond the preview
Go deeper on ChiCTR2500108379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108379.